New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
08:20 EDTAVNRAvanir weakness last night overdone, says JMP Securities
After Avanir reported that a Phase II trial for its MS treatment had missed its primary efficacy endpoint and the stock fell 17.5% in after-hours trading, JMP Securities says that the trial results were not expected to be positive. The firm reiterates a $7 price target and Outperform rating on the shares.
News For AVNR From The Last 14 Days
Check below for free stories on AVNR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AVNR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use